Sterility testing in compounded peptides: what the standards require
The standards exist. Compliance varies. Patients have a right to know which is which.
TL;DR
- Compounded sterile peptide preparations must meet USP <797> sterility standards in the United States.
- End-product sterility testing typically uses a 14-day microbial growth test on finished vials before release.
- A PCAB-accredited 503A pharmacy is one of the strongest public signals that the standards are not just on paper.
What it is
USP <797> (in plain English: the United States Pharmacopeia chapter that sets standards for sterile drug compounding) defines how a 503A compounding pharmacy must prepare, test, and release any injectable medication, including injectable peptides (USP, General Chapter <797>). The chapter is adopted as enforceable law by most state pharmacy boards.
How it works
Picture a kitchen-grade clean room with strict rules: filtered air, controlled pressure, gowned technicians, surface monitoring, and end-product checks. Every batch of compounded injectable peptide goes through that room. After the batch is sealed in vials, samples are pulled and incubated for 14 days. If anything grows during that window, the batch fails and is destroyed. If nothing grows, the batch is released. That is the loop USP <797> requires.
Who asks about it
People usually ask this question when comparing two pharmacies — or when they have read enough horror stories to want a real answer. The honest answer: the standards are good. Compliance is what varies. Asking the right questions is the patient’s leverage.
What the published research says
USP <797> was last revised in 2023 with stricter environmental monitoring and personnel competency requirements. The FDA’s compounding regulations under section 503A of the Federal Food, Drug, and Cosmetic Act require state-licensed pharmacies to follow USP standards for sterile compounding (FDA Compounding Laws and Policies). PCAB (Pharmacy Compounding Accreditation Board) accreditation, awarded by the Accreditation Commission for Health Care, is an independent verification of those standards.
What to know before considering it
Compounded peptides are not FDA-approved finished drug products. Sterility is one quality dimension; potency, identity, and stability are others. Reasonable patient questions include: Is this pharmacy PCAB-accredited? Will you provide a certificate of analysis for my batch? What is your sterility-testing turnaround? A pharmacy that cannot or will not answer these is a signal.
The Halftime POV
Sterility testing is invisible to most patients. That is why the standards matter — and why it is fair to ask the pharmacy to show its work. The right partners welcome the question. The wrong partners get defensive.
Related reading:
- 503A vs 503B compounding pharmacies explained
- What PCAB accreditation means for compounding pharmacy quality
- 503A pharmacy quality standards: what to look for
FAQ
Q: How are compounded peptides tested for sterility? A: USP General Chapter <797> sets the sterility testing standards. Pharmacies test finished compounded sterile preparations using a 14-day membrane filtration test or direct inoculation, depending on the volume. The preparation cannot be released to patients until the test confirms no microbial growth.
Q: What is USP <797>? A: USP <797> is the chapter of the United States Pharmacopeia that sets standards for compounded sterile preparations. It covers facility design, training, environmental monitoring, and end-product testing. Most state pharmacy boards adopt USP <797> as enforceable law.
Q: Do all 503A pharmacies do sterility testing? A: All 503A pharmacies that compound sterile preparations are required to comply with USP <797>. Compliance and quality vary in practice. PCAB-accredited pharmacies undergo independent quality verification, which is a useful signal.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding — Sterile Preparations.
- FDA. Human Drug Compounding: Compounding Laws and Policies.
